ROSALIE GARZA: Open Payments
NPI 1841809357 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,469 in 73 payments from 13 companies in 2025. Trend: 2023 $1,110 · 2024 $1,208 · 2025 $1,469
Food & beverage: $1,469
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $315 |
| Lilly USA, LLC | 12 | $275 |
| Novo Nordisk Inc | 15 | $264 |
| ABBVIE INC. | 11 | $182 |
| Sumitomo Pharma America, Inc. | 12 | $157 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $107 |
| Merck Sharp & Dohme LLC | 2 | $37 |
| PFIZER INC. | 2 | $31 |
| Amgen Inc. | 1 | $25 |
| GlaxoSmithKline, LLC. | 1 | $23 |
Products named: FARXIGA, Rybelsus, GEMTESA, KISUNLA, JARDIANCE, UBRELVY, AIRSUPRA, MOUNJARO.
Industry payments across TX — which companies pay providers there.
